Early ReportAssociation between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
Introduction
Clostridium difficile antibiotic-associated diarrhoea is a common, iatrogenic, nosocomial disease associated with substantial morbidity and mortality.1 Pathogenic strains of C difficile produce the protein exotoxins toxin A and toxin B. These cytotoxic, enterotoxic, and proinflammatory toxins induce colonic mucosal injury, diarrhoea, and in severe cases, pseudomembranous colitis.1, 2C difficile is endemic in hospitals and long-term care facilities throughout the world.3, 4, 5, 6, 7 In a previous study, we noted that 31% of patients who received antibiotics in acute-care medical wards were colonised by C difficile while in hospital. 56% of these developed C difficile diarrhoea; the remainder were symptomless carriers.3
Most patients with C difficile diarrhoea respond well to medical therapy that includes discontinuation of the inciting antibiotic and treatment with metronidazole or vancomycin.1, 8, 9 However, despite successful treatment of initial episodes, recurrence of diarrhoea after withdrawal of specific antibiotic therapy is a substantial clinical difficulty. Recurrence rates of 5-65% have been reported, dependent on definition of recurrence and population studied.10, 11, 12, 13, 14
We reported high concentrations of serum IgG against toxin A in symptomless carriers of C difficile.3 On the basis of this finding, and on results of our previous studies, we postulated that host immune response to toxin A during an episode of C difficile diarrhoea could affect risk of recurrence.15, 16
Section snippets
Patients
All patients with C difficile diarrhoea at Beth Israel Deaconess Medical Center, Boston, USA, between Jan 5, and May 22, 1998, were eligible for study enrolment. Diarrhoea was defined as a change in bowel habit with three or more unformed bowel movements per day for at least 2 days. C difficile diarrhoea was defined as diarrhoea not attributed to any other cause, that arose during or within 30 days of antibiotic therapy, and that was associated with a positive stool toxin for C difficile
Results
We prospectively identified 63 cases of C difficile diarrhoea during the 5-month study period. The study population was made up predominantly of elderly white patients, most had clinically significant comorbid disease, and almost two thirds (39, 62%) had severe or extremely severe underlying disease at hospital admission.
The presence or absence of recurrent diarrhoea could not be determined in 19 (30%) patients with C difficile diarrhoea because they died before the end of the 60-day follow-up
Discussion
In our prospective cohort study of 63 patients, we found that an acquired immune response to C difficile toxin A during an initial episode of C difficile diarrhoea is associated with a substantially reduced risk of recurrent diarrhoea. Patients with a single episode of C difficile diarrhoea have significantly higher concentrations of serum IgM against toxin A by day 3 of their illness and significantly higher serum concentrations of IgG against toxin A on day 12, than patients who later had
References (28)
- et al.
Incidence and impact of Clostridium difficile infection in the UK, 1993–1996
J Hosp Infect
(1998) - et al.
Clostridium difficile colitis: factors influencing treatment failure and relapse–a prospective evaluation
Am J Gastroenterol
(1998) - et al.
Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin
J Pediatr
(1991) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
Assessing illness severity: does clinical judgment work?
J Chronic Dis
(1986) - et al.
Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding
Gastroenterology
(1992) - et al.
Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea
Diagn Microbiol Infect Dis
(1994) - et al.
Clostridium difficile colitis
N Engl J Med
(1994) Pathogenesis of Clostridium difficile -associated diarrhoea
Eur J Gastroenterol Hepatol
(1996)- et al.
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A
N Engl J Med
(2000)
Nosocomial acquisition of Clostridium difficile infection
N Engl J Med
Clostridium difficile colonization and diarrhea at a tertiary care hospital
Clin Infect Dis
Clostridium difficile -associated disease in long-term care facilities
Infect Control Hosp Epidemiol
Guidelines for the diagnosis and management of Clostridium difficile -associated diarrhea and colitis
Am J Gastroenterol
Cited by (687)
Clostridioides difficile: from “difficult to grow” to “difficult to treat”
2023, Molecular Medical Microbiology, Third EditionJapanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection
2022, Journal of Infection and ChemotherapyCharacteristics and management of children with Clostridiodes difficile infection at a tertiary pediatric hospital in China
2022, Brazilian Journal of Infectious Diseases